Welcome to our dedicated page for Xencor SEC filings (Ticker: XNCR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Xencor, Inc. (XNCR) SEC filings page on Stock Titan provides access to the company’s official regulatory disclosures, including current reports on Form 8-K and other documents filed with the U.S. Securities and Exchange Commission. As a clinical-stage biopharmaceutical company developing engineered antibodies for cancer and autoimmune diseases, Xencor uses its SEC filings to report material events, financial results and key corporate developments related to its XmAb® technology platform and pipeline.
Investors can review Form 8-K filings in which Xencor reports quarterly financial results, such as revenue from collaborations, milestones and royalties, research and development expenses, and cash and marketable securities balances. These filings often incorporate press releases that summarize progress in clinical programs like XmAb819, XmAb541, plamotamab, XmAb657, XmAb942 and XmAb412, as well as updates on partnered programs and royalty-bearing products.
Xencor’s SEC filings also cover corporate actions and governance changes, including board appointments and director compensation, and Regulation FD disclosures related to investor presentations and webcasts. For example, the company has filed 8-Ks to furnish presentation materials and press releases discussing initial Phase 1 results of XmAb819 and early data from XmAb541, along with associated clinical timelines.
On Stock Titan, these filings are complemented by AI-powered summaries that highlight the most important points in each document, helping readers quickly understand the implications of new information. Users can monitor real-time updates from EDGAR, track items related to financial condition, material clinical data disclosures, and governance events, and use the structured view of XNCR filings to follow how Xencor’s antibody engineering business and pipeline are reflected in its regulatory reporting.
Xencor, Inc. is asking stockholders to approve several items at its June 16, 2026 annual meeting, including an amendment to its 2023 Equity Incentive Plan to add 4,000,000 shares, about 5.4% of shares outstanding as of March 31, 2026, designed to cover roughly one year of equity grants. Stockholders will also vote on electing nine directors, ratifying KPMG LLP as auditor for 2026, and an advisory say-on-pay for executives. Xencor ended 2025 with $610.8 million in cash, cash equivalents and marketable securities and highlights multiple oncology and autoimmune programs, including XmAb819 and XmAb541 in solid tumors, TL1A antibodies XmAb942 and XmAb412 in inflammatory bowel disease, and B‑cell–targeted bispecifics plamotamab and XmAb657 in autoimmune diseases.
Xencor, Inc. adopted a new Executive Severance Policy covering its currently serving named executive officers other than the Chief Executive Officer. Eligible executives must sign a participation agreement to receive benefits.
If Xencor terminates an eligible executive without Cause or the executive resigns for Good Reason outside a change in control period and the executive signs a release, the executive is entitled to a lump-sum payment equal to 15 months of base salary plus up to 15 months of paid COBRA health coverage.
If such a termination occurs during a defined change in control period, the executive also receives bonus compensation equal to 15 months of target bonus, a prorated annual bonus, and accelerated vesting of all outstanding, unvested stock options and equity awards, subject to a release of claims.
Xencor Inc senior vice president and CFO Bart Jan Cornelissen reported a sale of 3,499 shares of common stock on April 10, 2026 at an average price of $12.2865 per share. According to the filing, these shares were sold to pay withholding taxes upon the vesting of 14,088 restricted stock units, making this a compensation-related, tax-driven transaction rather than a discretionary open-market sale. After this sale, Cornelissen directly owned 75,898 shares of Xencor common stock.
XNCR notice under Rule 144 reporting the proposed sale of 3,499 shares of Common Stock related to restricted stock vesting on 04/09/2026. The filing also shows 2,517 shares of Common Stock reported sold on 03/05/2026 by Bart Jan Cornelissen.
Xencor, Inc. Schedule 13G shows RA Capital Management, L.P., RA Capital Healthcare Fund, L.P., and named managers Peter Kolchinsky and Rajeev Shah report shared beneficial ownership of 4,736,739 shares, representing 6.5% of common stock based on 73,338,642 shares outstanding as of February 17, 2026.
The filing states the Fund directly holds the shares and has delegated voting and dispositive powers to RA Capital; the Reporting Persons disclaim group status and certain beneficial ownership for Section 13(d) purposes.
Xencor Inc ownership filing shows The Vanguard Group reports 0 shares beneficially owned, representing 0% of common stock. The amendment explains an internal realignment effective January 12, 2026 that caused certain subsidiaries to report separately and disaggregate prior holdings.
The filing is signed by Ashley Grim as Head of Global Fund Administration on March 27, 2026 and states The Vanguard Group has no sole or shared voting or dispositive power over Xencor common shares in this report.
Xencor Inc senior executive reports tax-related share sales. SR. Vice President & CSO John R. Desjarlais sold a total of 6,620 shares of Xencor common stock in open-market transactions on March 5 and March 6. The sales were made solely to cover withholding taxes upon vesting of restricted stock units. Following these transactions, he directly holds 263,831 Xencor shares.
Xencor Inc (XNCR) senior vice president and general counsel Celia Eckert reported tax-related sales of company stock. On two days in early March, she sold a total of 5,011 shares of Xencor common stock in open-market transactions at prices around $11 per share.
The footnotes explain these were dispositions of shares sold to pay withholding taxes upon vesting of 7,316 and 4,363 restricted stock units, rather than discretionary share sales. After these transactions, she continued to hold 76,918 Xencor common shares directly.
Xencor Inc. senior vice president and CFO Bart Jan Cornelissen reported an open-market sale of 2,517 shares of common stock on March 5, 2026 at an average price of $11.2455 per share. According to the footnote, these shares were sold to pay withholding taxes upon the vesting of 7,316 restricted stock units, indicating a tax-related transaction rather than a discretionary sale. After this sale, Cornelissen directly holds 79,397 shares of Xencor common stock.